China Approves First Class 3.1 Classical Formula Drug Zhenwu Tang Granules, Marking TCM Modernization Milestone
核心洞察
China's National Medical Products Administration (搜索) (NMPA) has approved Zhenwu Tang Granules (搜索), representing one of the first successful cases under the Class 3.1 classical formula drug pathway for traditional Chinese medicine.
The approval demonstrates the integration of ancient medical prescriptions into modern pharmaceutical development systems with standardized manufacturing and quality control processes.
Zhenwu Tang Granules (搜索), derived from the classical text Treatise on Febrile Diseases, addresses Yang deficiency (搜索) and fluid metabolism disorders across multiple therapeutic areas including cardiology and nephrology.
China's National Medical Products Administration (搜索) (NMPA) has granted marketing approval to Zhenwu Tang Granules (搜索), a traditional Chinese medicine developed under the Class 3.1 classical formula drug pathway. The approval, achieved through joint research by Hunan Yineng Biopharmaceuticals Co., Ltd. (搜索) and submitted by Kangpu Pharmaceutical Co., Ltd. (搜索), represents one of the first successful cases under this regulatory framework and marks a significant milestone in the modernization of classical Chinese medicine.
Regulatory Innovation in Traditional Medicine
The Class 3.1 category represents a structured approach to transforming traditional empirical medicine into standardized pharmaceutical products suitable for evidence-based clinical application. This pathway specifically applies to traditional Chinese medicine products developed from the National List of Ancient Classical Formulas (First Batch) issued by Chinese regulatory authorities.
The regulatory framework requires products to be derived from validated ancient medical literature, undergo historical formula verification and documentation, complete modern pharmaceutical development processes, and implement standardized manufacturing and quality control systems. According to the source materials, this pathway is currently one of the most clearly defined regulatory routes for TCM innovation in China.
Clinical Profile and Therapeutic Applications
Zhenwu Tang originates from the classical medical text Treatise on Febrile Diseases (Shang Han Lun) and addresses conditions related to Yang deficiency (搜索) and fluid metabolism imbalance (搜索). The formula consists of five herbal components: processed Aconite root (搜索), Atractylodes macrocephala (搜索), Poria (搜索), white peony root, and fresh ginger (搜索).
The therapeutic functions include warming Yang and supporting metabolic balance, promoting diuresis and fluid regulation, and addressing systemic fluid retention disorders (搜索). Clinical applications span multiple medical specialties including cardiology, nephrology, respiratory medicine, endocrinology, gastroenterology, and gynecology.
The formula is associated with a broad spectrum of chronic conditions such as edema (搜索), fatigue (搜索), cold extremities, and systemic fluid imbalance, indicating strong long-term clinical demand according to the approval documentation.
Modern Pharmaceutical Development
Hunan Yineng Biopharmaceuticals Co., Ltd. (搜索) played a key role in bridging traditional medical knowledge with modern pharmaceutical engineering systems. The development process incorporated several critical elements: herbal source standardization to ensure consistent botanical origin and reduce variability across production batches, CMC process optimization to improve extraction efficiency and stabilize active ingredient composition through controlled manufacturing processes, and an end-to-end quality control system implementing full lifecycle quality management from raw materials to finished dosage forms.
The granule dosage form represents a significant advancement over traditional preparations. According to the source materials, the granule formulation significantly improves patient adherence, dosage convenience, and clinical usability in outpatient treatment settings, enhancing both scalability and real-world clinical adoption.
Industry Impact and Market Implications
The approval of Zhenwu Tang Granules (搜索) reflects broader structural changes in China's traditional medicine industry. Key industry developments include increasingly predictable classical formula approval pathways, transformation of ancient prescriptions into scalable drug products, growing demand for TCM R&D and CMC service providers, and accelerating integration between traditional medicine and modern clinical systems.
These developments position classical formula drugs as a rapidly expanding segment within China's pharmaceutical innovation ecosystem. The success of this approval pathway demonstrates that ancient medical prescriptions are increasingly being integrated into modern pharmaceutical development systems with clear regulatory and industrial pathways.
Manufacturing and Quality Standards
The development process addressed key challenges in TCM new drug development, including raw material consistency, process standardization, quality control, and clinical validation. The transformation from traditional preparation methods to modern pharmaceutical manufacturing represents a significant advancement in ensuring product consistency and therapeutic reliability.
Companies participating in classical formula development typically require capabilities in pharmaceutical R&D, CMC development, regulatory submission, and integrated quality systems, according to the industry analysis provided in the source materials.